Skip to content
Open access

Effect of Partha Vati in Medoroga with special reference to Dyslipidemia and in Enhancing Cardioprotective Activity

Aug 2026 · International journal of Ayurveda and pharma research · pp. 18-30 · 0 citations

TL;DR

The drug Partha Vati was found to be effective in Medoroga with special reference to dyslipidemia and in enhancing cardioprotective activity and was found to be statistically significant in Medoroga.

Abstract

Medoroga, a highly prevalent disease in the society today due to modified lifestyle, sedentary mode, of majority of people causing various systemic illnesses demanding lifelong medications due to its relapsing nature. Dyslipidemia has been strongly associated with the pathophysiology of cardiovascular diseases and is a major independent risk factor for coronary artery disease. Despite the well documented benefits of statin, people undergoing statin therapy are frequently challenged with various adverse reactions. Based on this background a better, safe and effective medication is the need of the hour. Thus, Partha Vati, an Anubhuta yoga was selected and this study was aimed to find the effect of Partha Vati in Medoroga with special reference to dyslipidemia and in enhancing cardioprotective activity. The trial was a pre and post interventional study. A total of 38 subjects were selected and all of them completed the trial. The interventional drug Partha Vati was given as 250mg tablet, morning and night amidst meal, for continuous 30 days. Graded criteria were assessed on 0th and 31st day. Data regarding all the variables were collected and analysed statistically. The results of the test were found to be statistically significant with a P value <0.001 except for Athikshut which means the intervention helped to decrease the signs and symptoms of Medoroga. The medicine was found to be effective and statistically significant in Medoroga. Hence the drug Partha Vati was found to be effective in Medoroga with special reference to dyslipidemia and in enhancing cardioprotective activity.

Read PDF

Similar papers

Open access Aug 2026

Protocol for an Open Labelled Parallel Comparative Clinical Study to Evaluate the Efficacy of Karkashdaladi Kwath and Navaka Guggulu in the Management of Medodushti with Special Reference to Dyslipidemia

Background: Dyslipidemia can be correlated with Medodushti as described in Ayurveda. It is characterized by abnormal lipid metabolism and is highly prevalent worldwide. Dyslipidemia is one of the major modifiable risk factors for diabetes mellitus, obesity, chronic heart diseases, and thyroid disorders. Although statin...

Charu Walia, Neelam Kumari, Neha Lamba · 0 citations
Open access Aug 2026

RATIONALITY OF USE OF ANTIHYPERLIPIDEMIA DRUGS IN THE PHARMACY INSTALLATION

The use of antihyperlipidemia drugs in hyperlipidemia patients at the Pharmacy Unit of Regional Hospital in 2024 was largely rational, and the 56-65 age group was the most likely group to suffer from hyperlipidemia.

Burhanudin Gasim Soka, Sovy Ayu Rahmawati, Fauzi Rahman · 0 citations
Review Open access Aug 2026

THE ROLE OF NUTRACEUTICALS IN THE MANAGEMENT OF DYSLIPIDEMIA AND THEIR EFFECTS ON LIPID METABOLISM: A SYSTEMATIC REVIEW

Dyslipidemia is one of the top modifiable causes of ASCVD‚ which is still the leading cause of death worldwide․ Statins are first line treatment‚ but potentially reversible obstacles to effective treatment include patient discontinuation‚ statin intolerance‚ concern about statin-related adverse effects‚ and residual ca...

K. Jurga, Maurycy Jabłoński, Laura Kobaka et al. · 0 citations
Open access Oct 2026

EFFECTIVENESS OF EMPAGLIFLOZIN AND LINAGLIPTIN AS ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES: PHYSICIAN INSIGHTS FROM SOUTHERN INDIA

Background: Type 2 diabetes mellitus (T2DM) is a chronic global health burden associated with cardiovascular (CV) and renal complications. This study aimed to evaluate real-world efficacy, cardiometabolic outcomes, and long-term outcomes of the empagliflozin + linagliptin add-on therapy to metformin in T2DM patients. M...

Nandkishor Shingne, Vrunda Patel, Swati Tiwari et al. · 0 citations
Review

of Pharma and Biomedics

Numan Asghar, Farid Ullah, Sadam Hussain et al. · 0 citations
Open access Oct 2026

Metabolic-associated fatty liver disease and hypertriglyceridemia: cardiovascular risks and current therapeutic approaches

Metabolic-associated fatty liver disease (MAFLD) is a systemic disorder associ-ated with metabolic dysfunction and a high risk of life-threatening conditions, primarily cardiovascular disease. MAFLD is often accompanied by hypertriglyceridemia (HTG), as both conditions share a common pathogenetic mechanism — insulin re...

Y. Khalimov, M. Yezhov, K. Raikhelson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.